NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Forecast, Price & News

$27.03

-0.22 (-0.81%)

(As of 09:46 AM ET)

Compare

Today's Range: $26.68
▼
$27.32
50-Day Range: $24.29
▼
$33.80
52-Week Range: $17.86
▼
$34.28

Volume: 119,324 shs
Average Volume: 725,049 shs
Market Capitalization: $2.77 billion

P/E Ratio: 32.57
Dividend Yield: N/A
Price Target: $30.81

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.43 Rating Score
Upside/Downside: 13.1% Upside
$30.81 Price Target
Short Interest: Bearish
16.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.96
Upright™ Environmental Score
News Sentiment: 0.89
Based on 10 Articles This Week
Insider Trading: Selling Shares
$2.75 M Sold Last Quarter
Proj. Earnings Growth: 6.41%
From $0.78 to $0.83 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

399th out of 968 stocks

Pharmaceutical Preparations Industry

170th out of 453 stocks

2.2

Analyst's Opinion

Consensus Rating
Corcept Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.81, Corcept Therapeutics has a forecasted upside of 13.1% from its current price of $27.25.
Amount of Analyst Coverage
Corcept Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
16.58% of the float of Corcept Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Corcept Therapeutics has a short interest ratio ("days to cover") of 24.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Corcept Therapeutics has recently decreased by 2.16%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Corcept Therapeutics does not currently pay a dividend.
Dividend Growth
Corcept Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corcept Therapeutics has received a 62.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sex hormones and modulators of the genital system (G03)", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Corcept Therapeutics is -0.96.

3.3

News and Social Media Coverage

News Sentiment
Corcept Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Corcept Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
3 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,746,228.00 in company stock.
Percentage Held by Insiders
18.60% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.80% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Corcept Therapeutics are expected to grow by 6.41% in the coming year, from $0.78 to $0.83 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corcept Therapeutics is 32.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.59.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corcept Therapeutics is 32.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.18.
Price to Book Value per Share Ratio
Corcept Therapeutics has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Price History

30 days | 90 days | 365 days | Advanced Chart

CORT Stock News Headlines

October 1, 2023 | americanbankingnews.com

Corcept Therapeutics (NASDAQ:CORT) Sees Large Volume Increase

September 30, 2023 | msn.com

Corcept Therapeutics plunges amid patent trial with Teva (update)

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 29, 2023 | seekingalpha.com

Corcept Therapeutics plunges amid patent trial with Teva

September 29, 2023 | finance.yahoo.com

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

September 29, 2023 | americanbankingnews.com

Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $30.81 Consensus Price Target from Analysts

September 28, 2023 | finance.yahoo.com

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

September 26, 2023 | finance.yahoo.com

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

October 2, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.

September 25, 2023 | stocknews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

September 23, 2023 | americanbankingnews.com

Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $812,000.00 in Stock

September 23, 2023 | americanbankingnews.com

Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $812,000.00 in Stock

September 22, 2023 | finance.yahoo.com

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

September 22, 2023 | americanbankingnews.com

Q2 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lifted by Zacks Research

September 21, 2023 | benzinga.com

Massive Insider Trade At Corcept Therapeutics

September 19, 2023 | finance.yahoo.com

Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?

September 12, 2023 | finance.yahoo.com

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

September 7, 2023 | finance.yahoo.com

Decoding Corcept Therapeutics (CORT)'s Market Value: An In-Depth Analysis

September 7, 2023 | finance.yahoo.com

Corcept Therapeutics Inc's Meteoric Rise: Unpacking the 36% Surge in Just 3 Months

September 6, 2023 | finance.yahoo.com

Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?

September 1, 2023 | finance.yahoo.com

Why Is Corcept (CORT) Up 4.8% Since Last Earnings Report?

August 30, 2023 | stocknews.com

Unlocking Biotech's Potential With 3 Stocks to Buy

August 29, 2023 | finance.yahoo.com

Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?

August 26, 2023 | msn.com

Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)

August 25, 2023 | msn.com

Canaccord Genuity Maintains Corcept Therapeutics (CORT) Buy Recommendation

August 25, 2023 | markets.businessinsider.com

Expert Ratings for Corcept Therapeutics

August 25, 2023 | finance.yahoo.com

Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio

See More Headlines

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings: 8/02/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:CORT
CUSIP: 21835210
CIK: 1088856
Web: www.corcept.com
Phone: (650) 327-3270
Fax: 650-327-3218
Employees: 299
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $30.81
High Stock Price Forecast: $47.50
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +13.1%
Consensus Rating: Hold
Rating Score (0-4): 2.43
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.83
Trailing P/E Ratio: 32.83
Forward P/E Ratio: 34.94
P/E Growth: N/A
Net Income: $101.42 million
Net Margins: 22.02%
Pretax Margin: 25.38%
Return on Equity: 19.57%
Return on Assets: 16.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.65
Quick Ratio: 4.57

Sales & Book Value

Annual Sales: $401.86 million
Price / Sales: 6.95
Cash Flow: $0.97 per share
Price / Cash Flow: 28.13
Book Value: $4.66 per share
Price / Book: 5.85

Miscellaneous

Outstanding Shares: 102,550,000
Free Float: 82,243,000
Market Cap: $2.79 billion
Optionable: Optionable
Beta: 0.45

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Joseph K. Belanoff M.D. (Age 66)
Co-Founder, Pres, CEO & Director
Comp: $1.82M

Mr. Atabak Mokari (Age 46)
CFO & Treasurer
Comp: $760.75k

Dr. Hazel Hunt Ph.D. (Age 63)
Chief Scientific Officer
Comp: $895.16k

Mr. Sean Maduck (Age 46)
Pres of Corcept Endocrinology
Comp: $823.42k

Mr. Gary Charles Robb (Age 60)
Chief Bus. Officer & Sec.
Comp: $963k

Mr. Joseph Douglas Lyon (Age 44)
Chief Accounting Officer

Ms. Amy Flood
Chief HR & Communications Officer

Dr. William Guyer Pharm.D. (Age 55)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CORT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CORT, but not buy additional shares or sell existing shares.
View CORT analyst ratings or view top-rated stocks.
What is Corcept Therapeutics' stock price forecast for 2023?: 7 Wall Street analysts have issued 1-year price objectives for Corcept Therapeutics' stock. Their CORT share price forecasts range from $22.00 to $47.50. On average, they predict the company's stock price to reach $30.81 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.
How have CORT shares performed in 2023?: Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 34.2% and is now trading at $27.25.
View the best growth stocks for 2023 here.
When is Corcept Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CORT earnings forecast.
How were Corcept Therapeutics' earnings last quarter?: Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.10. The biotechnology company had revenue of $117.72 million for the quarter, compared to the consensus estimate of $109.60 million. Corcept Therapeutics had a net margin of 22.02% and a trailing twelve-month return on equity of 19.57%. The company's revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 EPS.
What ETFs hold Corcept Therapeutics' stock?: ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Hartford Multifactor Small Cap ETF (ROSC) and Distillate Small/Mid Cash Flow ETF (DSMC).
What guidance has Corcept Therapeutics issued on next quarter's earnings?: Corcept Therapeutics updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.00 million-$470.00 million, compared to the consensus revenue estimate of $443.89 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?: 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Corcept Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).
What is Corcept Therapeutics' stock symbol?: Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How do I buy shares of Corcept Therapeutics?: Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Corcept Therapeutics' stock price today?: One share of CORT stock can currently be purchased for approximately $27.25.
How much money does Corcept Therapeutics make?: Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.79 billion and generates $401.86 million in revenue each year. The biotechnology company earns $101.42 million in net income (profit) each year or $0.83 on an earnings per share basis.
How many employees does Corcept Therapeutics have?: The company employs 299 workers across the globe.
How can I contact Corcept Therapeutics?: Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial